Investment Thesis
Hoth Therapeutics is operationally unprofitable with negative cash burn of $3.1M annually and limited cash runway of approximately 1.3 years. Despite strong liquidity ratios and zero debt, the company shows deteriorating financial health with negative ROE/ROA and must achieve profitability or secure additional funding to survive.
Strengths
- Strong cash position of $4.0M with zero long-term debt
- Excellent liquidity ratios (3.39x current ratio) providing short-term financial flexibility
- Minimal leverage reduces bankruptcy risk in the near term
Risks
- Significant cash burn of $3.1M annually with limited runway before additional funding becomes critical
- Persistent operating losses and negative profitability with poor capital returns (ROE -64.7%, ROA -48.1%)
- Pharmaceutical sector execution risk with no demonstrated path to sustainable profitability
Key Metrics to Watch
- Operating cash flow trajectory and quarterly cash burn rate trends
- Path to profitability and quarterly operating income improvements
- Revenue sustainability and evidence of gross margin expansion
Financial Metrics
Revenue
1.2B
Net Income
-2.7M
EPS (Diluted)
$-0.17
Free Cash Flow
-3.1M
Total Assets
5.6M
Cash
4.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-0.2%
Net Margin
-0.2%
ROE
-64.7%
ROA
-48.1%
FCF Margin
-0.2%
Balance Sheet & Liquidity
Current Ratio
3.39x
Quick Ratio
3.39x
Debt/Equity
0.00x
Debt/Assets
25.6%
Interest Coverage
-18.39x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:32:10.336248 |
Data as of: 2026-03-31 |
Powered by Claude AI